Nautilus Biotechnology (NAUT) to Release Earnings on Thursday

Nautilus Biotechnology (NASDAQ:NAUT) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Nautilus Biotechnology Stock Performance

Shares of NAUT stock opened at $2.82 on Friday. Nautilus Biotechnology has a 52-week low of $0.62 and a 52-week high of $2.93. The stock has a market cap of $356.19 million, a price-to-earnings ratio of -5.64 and a beta of 1.49. The firm’s 50-day moving average is $2.08 and its 200-day moving average is $1.51.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its position in shares of Nautilus Biotechnology by 5.4% in the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock valued at $1,989,000 after purchasing an additional 52,448 shares during the period. Bridgeway Capital Management LLC grew its stake in Nautilus Biotechnology by 4.0% in the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after buying an additional 5,000 shares in the last quarter. Captrust Financial Advisors bought a new stake in Nautilus Biotechnology during the 4th quarter valued at $66,000. OMERS ADMINISTRATION Corp bought a new stake in Nautilus Biotechnology during the 4th quarter valued at $204,000. Finally, Marshall Wace LLP purchased a new stake in shares of Nautilus Biotechnology during the fourth quarter worth $228,000. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on NAUT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell” and an average target price of $2.50.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.